The gene encoding PTPROt (truncated isoform of protein tyrosine phosphatase receptor-type O) is methylated and suppressed in chronic lymphocytc leukemia (CLL). PTPROt exhibits in vitro tumor-suppressor characteristics through the regulation of B-cell receptor (BCR) signaling. Here we generated transgenic (Tg) mice with B-cell-specific expression of PTPROt. Although lymphocyte development is normal in these mice, crossing them with TCL1 Tg mouse model of CLL results in a survival advantage compared with the TCL1 Tg mice. Gene expression profiling of splenic B-lymphocytes before detectable signs of CLL followed by Ingenuity Pathway Analysis revealed that the most prominently regulated functions in TCL1 Tg vs non-transgenic (NTg) and TCL1 Tg vs PTPROt/TCL1 double Tg are the same and also biologically relevant to this study. Further, enhanced expression of the chemokine Ccl3, the oncogenic transcription factor Foxm1 and its targets in TCL1 Tg mice were significantly suppressed in the double Tg mice, suggesting a protective function of PTPROt against leukemogenesis. This study also showed that PTPROt-mediated regulation of Foxm1 involves activation of p53, a transcriptional repressor of Foxm1, which is facilitated through suppression of BCR signaling. These results establish the in vivo tumor-suppressive function of PTPROt and identify p53/Foxm1 axis as a key downstream effect of PTPROt-mediated suppression of BCR signaling.
INTRODUCTION
Protein tyrosine phosphatase receptor-type O (PTPRO) is a membrane anchored tyrosine phosphatase with varied functions in different tissues. It was originally cloned as glomerular epithelial protein 1 (ref. 1) with function in glomerular filtration and podocyte structure. 2 This protein was also expressed at high level in the brain where it functions in axonogenesis and differentiation of neurons. 3 A truncated isoform (PTPROt) identified in B-lymphoid cells was found to promote cell cycle arrest. 4 A series of studies by our group and others have demonstrated its methylation and suppression in different types of cancers [5] [6] [7] [8] [9] [10] and its in vitro and ex vivo growth-suppressive characteristics. 5, 7, 8, 11 In addition to understanding its functions, several studies, including ours, have identified its substrates in different cell types, for example, eph receptors in axons, 12 SYK, Lyn and ZAP70 in lymphocytes, 13, 14 breakpoint cluster region (BCR)/ABL in myelogenous leukemia 11 and VCP in hepatocellular carcinoma. 5 Recent studies using a large number of human samples have demonstrated a prognostic function of PTPRO in breast cancer 15 and a biomarker function in esophageal squamous cell carcinoma. 16 These studies have thus highlighted the physiological significance of PTPRO expression and its deregulation in diseased states.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, with 16 060 new cases in 2012. 17 Despite advances made in treatment approaches and increase in 5-year relative survival rate over the past few decades, CLL remains incurable. A role of aberrant protein tyrosine kinase activity (for example, Lyn, SYK, ZAP70) and their downstream signaling supporting malignant proliferation and survival have been identified in CLL. Although the aberrant kinase activity is largely due to overexpression of tyrosine kinase genes, the lack of protein tyrosine phosphatase activity counterbalancing the kinase activity is also involved in the pathology of CLL. In this context, we have shown that PTPROt is significantly downregulated by transcriptional and epigenetic mechanisms in primary CLL 7 as well as in TCL1 Tg mouse model of CLL 18 relative to the respective normal B-cells. Further, PTPROt has an important role in BCR signaling by dephosphorylating BCR signaling components Lyn kinase 14 and Syk. 13 Additionally, ZAP70, a tyrosine kinase aberrantly expressed in B-CLL and predictive of worse outcome, is a bona fide substrate of PTPROt. 14 Despite all the indications of a critical role of PTPROt as a tumor suppressor in CLL, no studies have been performed to demonstrate its in vivo functions in the context of CLL. Further, several mechanisms of CLL tumorigenesis have been identified based on studies conducted with human CLL samples and mouse models of CLL. 19, 20 Among these mechanisms, aberrant expression of the TCL1 oncogene in CLL cells correlates with molecular subtypes and proliferation state. 21 Importantly, ectopic expression of TCL1 in mouse B-lymphocytes causes a lymphoproliferative disorder on aging that mimics human CLL, 22 and our previous studies have demonstrated suppression of PTPROt in this mouse model. 18 These observations provide the rationale for exploring the role of PTPROt in leukemogenesis using the TCL1 Tg model of CLL and the mechanism associated with it. Here we describe the generation of a transgenic mouse with PTPROt expression specifically in B-cells. These mice develop normally and live a normal life span. Further, they do not exhibit any defects in lymphocyte development. Crossing these mice with the TCL1 Tg mouse model of CLL alleviates the characteristics of CLL, such as increased spleen weight and accumulation of leukemic CD5/CD19 cell population. Additionally, the double Tg mice exhibit an increased lifespan compared with the TCL1 Tg mice. While exploring the mechanism of this protective function of PTPROt, we observed suppression of the chemokine Ccl3, a known marker of disease progression in CLL patients, and Foxm1 in the double Tg mice compared with the TCL1 Tg mice, implicating a direct role of Foxm1 in the pathogenesis of CLL. Further, we have demonstrated that inhibition of BCR signaling activates p53 to suppress FoxM1 expression in these mice.
MATERIALS AND METHODS Antibodies
Antibodies used for western blotting: anti-HA (Covance, Princeton, NJ, USA), anti-pY(416)Src, Src (Cell Signaling Technology, Danvers, MA, USA), anti-pY 4G10 (Upstate Biotechnology Inc, Lake Placid, NY, USA), anti-pY20, anti-pY99 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-p53 (Santa Cruz Biotechnology), anti-GAPDH (anti-glyceraldehyde 3-phosphate dehydrogenase; Millipore, Billerica, MA, USA), anti-Ku-70 (Neomarker, Fremont, CA, USA). The following antibodies used for flow cytometry were from Beckton Dickinson and Company (San Jose, CA, USA): B220, immunoglobulin M (IgM), CD4, CD8, CD5, CD11b, and GR-1.
Generation of PTPROt Tg mice and crossing with TCL1 Tg mice to obtain PTPROt/TCL1 double Tg mice
To express PTPROt specifically in the B-cell compartment of mice, human PTPROt cDNA was amplified using the primers 5′-CAGGATCCCAATGGTTAC AGAGATGAATCC-3′ and 5′-CTACTCGAGAGCGTAATCTGGAACGTCGTATG GGTAGGACTTGCTAACATTCTCG-3′ and cloned in the BamHI and XhoI sites of pEmu plasmid (the same plasmid that was used to express TCL1 in the B-cells 23 ). The restriction sites are underlined and the sequence corresponding to the HA tag is depicted in bold. Microinjection of linearized transgenic construct into zygotes, implantation of microinjected zygotes into pseudo-pregnant recipient mice and weaning of founder mice was performed at the Genetically Engineered Mouse Modeling Shared Resources at The Ohio State University Comprehensive Cancer Center. Tail clips from founder mice were used for genotyping by Southern blotting and PCR. Two founder lines were generated in C57BL6 background. Among these, founder line F1 had very low levels of PTPROt expression as detected by western blotting analysis, whereas founder line F2 had easily detectable levels of PTPROt expression ( Figure 1a ). Preliminary characterization of lymphocyte development performed on the two founder lines yielded similar results (data not shown). Thus data from the higher expressing founder line (F2) is presented here, and the remaining studies have been performed with this founder. Characterization of the PTPROt Tg mice was performed in C57BL6 background. To cross them with TCL1 Tg mice, they were first bred with C3H mice to obtain F1 generation in C57BL6/C3H background, the same background of TCL1 Tg mice. These mice were then crossed with homozygous TCL1 Tg mice to obtain both TCL1 Tg and PTPROt/TCL1 double Tg mice as littermates. One set of breeding was performed with hemizygous TCL1 Tg mice to obtain all four groups of mice (NTg, PTPROt Tg, TCL1 Tg and PTPROt/TCL1 double Tg) as littermates.
Lymphocyte development in PTPROt Tg mice
Lymph nodes, femur (for bone marrow), spleen and thymus were collected from 7-week-old NTg and PTPROt Tg mice (n = 3). Lymphocytes were flushed out from the femur using phosphate-buffered saline. Lymph nodes, thymus and spleen were gently crushed to release the lymphocytes. Red blood cells were removed from the suspension of spleen cells using ficoll gradient. One million cells were stained with the appropriate antibodies, and the respective isotype control antibodies were analyzed on FC500 flow cytometer (Beckman Coulter, Inc., Pasadena, CA, USA).
Microarray analysis and real-time reverse transcriptase-PCR (RT-PCR)
Spleen cells isolated from 4-month-old NTg, TCL1 Tg and PTPROt/TCL1 double Tg mice were sorted for CD19+ cells using CD19 microbeads (Miltenyi Biotec Inc, San Diego, CA, USA). Purity of the sorted cells assessed by flow cytometry following staining with CD5/CD19 antibodies was found to be 490%. RNA was extracted from the cells using Trizol followed by further purification. The RNA was then used for microarray analysis on Affymetrix platform (moGene1.0 ST), performed at the Nucleic Acids Shared Resources at the Ohio State University Comprehensive Cancer Center. The data were normalized using the RMA method. 24 The microarray data were deposited in the GEO database (GSE60582). We used analysis of variance to test differentially expressed genes using the SAS Suppression of leukemic phenotype in CLL mouse model by PTPROt software (SAS, Inc., Cary, NC, USA). Biological functions and gene networks that were altered between the different groups of mice were identified using the Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Inc., Redwood City, CA, USA). Expression of the selected genes was validated by real-time RT-PCR using the PrimeTime qPCR Assays IDT (Integrated DNA Technologies Inc, Coralville, IA, USA).
Cell treatments CD19-selected spleen lymphocytes isolated from TCL1 Tg mice were maintained in RPMI 1640 (Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Invitrogen), 2 mmol/l of L-glutamine (Invitrogen) at 37°C in a humidified incubator with 5% CO 2 . The cells were treated with 2.5 μM SYK inhibitor R406 (Selleckchem, Houston, TX, USA) and 2.5 μM BTK inhibitor PCI-32765 (Sellekchem) for 48 h.
Other statistics
Data with continuous variable were analyzed using the analysis of variance. Mouse survival data were plotted (Kaplan-Meier survival curves) and analyzed using the log-rank test. SAS software was used for data analysis.
RESULTS

Generation and preliminary characterization of PTPROt Tg mice
To evaluate the physiological significance of PTPROt in the context of CLL, we generated transgenic mice expressing HA-tagged PTPROt under the control of the V H promoter-Eμ enhancer, the same elements that drive TCL1 expression in TCL1 Tg mice. 23 The expression of transgene was evaluated in the whole cell extracts of spleen and thymus cells using antibody against HA-epitope. As anticipated, the transgene was specifically detected in the spleen but not in the thymus (Figure 1b ). Next, the phosphorylation state of previously identified substrates of PTPROt (Lyn and SYK) was studied in B-cells purified from the spleen by positive selection. Immunoblotting with anti-pY(416)Src that detects activated Src/Lyn demonstrated markedly reduced phosphorylation in Tg mice compared with NTg counterpart (Figure 1c ). In contrast, no alteration in phosphorylation of Src was observed in negatively selected cells (non-B-cells) used as controls (Figure 1c ), reinforcing tissue-specific expression and biochemical effects in response to PTPROt overexpression. Because a specific antibody against phosphorylated SYK was unavailable, we immunoprecipitated phosho-proteins from the whole cell extracts of spleen B-cells followed by immunoblotting with anti-SYK antibody to determine its phosphorylation state in the Tg mice. The data demonstrated diminished amount of SYK in the Tg sample following immunoprecipitation with anti-pY (Figure 1d ), suggesting that it was hypophosphorylated in the spleen B-cells from Tg mice.
Next, flow cytometric analysis was performed on 7-week-old mice to determine whether B-cell specific transgenic expression of PTPROt results in alterations of B-cell development in these mice. B220/IgM staining of cells from the bone marrow, spleen and lymph nodes was used to study the pre-B to B-cell transition. No significant alterations in the B220+/IgM+ population of cells were observed in these lymphoid organs (Figure 2a ). Additionally, T-cell development was also studied by flow cytometric analysis of CD4/CD8 cells in the thymus and spleen. This analysis also did not reveal any significant alterations in the CD4+/CD8+ population of cells in these lymphoid organs (Figure 2b) . Similarly, both B-and T-cell development were indistinguishable in Tg and NTg mice at 16 months of age (Supplementary Figure S1) . These data imply that any change in leukemic phenotype resulting from crossing PTPROt Tg mice with TCL1 Tg mice is not due to transgene effect on B-cell development.
Distinct gene expression profiles between spleen B-cells from PTPROt/ TCL1 double Tg and TCL1 Tg mice. To evaluate the in vivo tumorsuppressive function of PTPROt and understand the underlying mechanism, the PTPROt Tg mice were crossed to the TCL1 Tg mouse model of CLL. Western blotting analysis was performed to check the expression of TCL1 and of both PTPROt and TCL1 in the spleen B-cells from TCL1 Tg and PTPROt/TCL1 double Tg mice, respectively (Figure 3a) . Early changes in gene expression resulting from overexpression of PTPROt in TCL1 Tg background were assessed in 4-month-old mice by microarray analysis. NTg and PTPROt Tg mice were also included in the analysis for comparison. At the time of necropsy, a significant decrease in spleen weight (20%, P = 0.007) as well as the total number of cells (36%, P = 0.007) was noted in the PTPROt/TCL1 double Tg group relative to the TCL1 Tg group (Figures 3b and c) . It should be noted that there was no statistically significant difference in these parameters between NTg and PTPROt Tg mice. CD19+ B-cells from the spleens were used for microarray analysis on Affymetrix platform. Flow cytometry analysis confirmed > 90% purity of the CD19-sorted B-cells (data not shown). We next sought to identify functions and networks associated with changes in gene expression between TCL1 Tg and NTg or PTPROt/TCL1. IPA revealed that the most significantly regulated functions for both comparisons are the same and are also biologically relevant to these studies (Supplementary Figure S2) . These observations suggest that PTPROt could reduce the tumorigenic properties of lymphocytes expressing TCL1. The gene networks with functions in cell cycle, DNA replication, recombination, repair and cell death were upregulated in TCL1 Tg mice (relative to NTg mice) but downregulated in the PTPROt/TCL1 double Tg mice (relative to TCL1 Tg mice) (Figure 3d) . A functionally significant gene in this network is FoxM1, a member of the forkhead family of transcription factors that is emerging as a target for cancer diagnosis and therapies. FoxM1 has also recently been identified as a master regulator of proliferation of germinal centers. 25 Validation of microarray data by real-time RT-PCR indeed demonstrated increased expression of FoxM1 in the TCL1 Tg mice and relatively reduced expression in PTPROt/TCL1 double Tg mice (Figure 4a ). Its upregulation in the spleen B-lymphocytes of TCL1 Tg mice could thus explain their increased proliferation, 26 whereas its suppression in the double Tg mice suggests that PTPROt can reduce the proliferative potential of lymphocytes expressing TCL1. Interestingly, several other transcriptional targets of FoxM1 were also similarly upregulated in TCL1 Tg mice but not in the PTPROt/TCL1 double Tg mice relative to the NTg mice ( Supplementary Figure S3 and Supplementary Table S1 ). Among the cell cycle genes that are Foxm1 targets, Cdc20 and Cdc25c were also validated by real-time RT-PCR (Figures 4b and c) . As observed with phenotypic data (Figures 3b and c) , the expression of Foxm1 and Cdc20 was not significantly different between NTg and PTPROt Tg (Figures 4a and b) . Although there was a small but significant increase in Cdc25c in the PTPROt Tg mice relative to the NTg mice, the increase observed in TCL1 Tg mice and the relative decrease in PTPTOt/TCL1 double Tg mice is much more dramatic and significant (Figure 4c ). In addition to these cell cycle regulators, the expression of Ccl3 (chemokine (C-C motif) ligand 3) was also enhanced in TCL1 Tg mice and inhibited in the double Tg mice. The expression of human C-C motif chemokine ligand 3 CCL3), also known as macrophage inflammatory protein-1a, is induced in CLL cells by nurse-like cells through BCR signaling and, therefore, correlates with ZAP70 expression. 27 Further, levels of CCL3 protein in the plasma of CLL patients correlate with risk of progression. 28 Altered expression of Ccl3 in the TCL1 Tg and PTPROt/TCL1 double Tg mice was also validated by real-time RT-PCR (Figure 4d ). Again, similar to Foxm1 and Cdc20, the expression of Ccl3 was not significantly altered in the PTPROt Tg mice compared with the NTg mice (Figure 4d ). Interestingly, CCL3 expression in CLL is enhanced in response to BCR activation. 27 As PTPROt is a negative regulator of BCR signaling, 13, 14 it is logical to assume that altered expression of Ccl3 observed in the two groups of mice results from differential BCR signaling.
PTPROt expression in TCL1 Tg mice suppresses the population of leukemic and inflammatory cells in the spleen. Accumulation of CD5+/CD19+ B-cells, a characteristic feature of CLL, is also observed in the TCL1 tg mice. 23 To determine whether the expression of PTPROt rescues this disease phenotype in double Tg mice, flow cytometry analysis was performed on spleen cells from the 8-month-old mice. This time point was selected because TCL1 Tg mice exhibit dramatic increase in the leukemic CD5+/CD19+ cell population at this time. 23 The data indeed demonstrate a significant reduction in CD5+/CD19+ spleen cells in the double Tg mice relative to the TCL1 Tg mice (Figure 5a ). Here again, no significant difference in the distribution of cell populations was observed between NTg and PTPROt Tg mice (Figure 5a) . A plot of the absolute numbers of CD5+/CD19+ cells reflects the dramatic increase observed in TCL1 Tg mice (Figure 5b, left panel) . Conversely, a plot of the absolute numbers of CD5 − /CD19+ cells shows a reduction of this population of cells in the TCL1 Tg mice (Figure 5b, right panel) . The upregulation of Ccl3, a chemoattractant for monocytes, macrophages, dendritic cells as well as CD8 + T-cells, prompted us to assess these cells in the spleens of TCL1 Tg and double Tg mice. As expected, a higher proportion of spleen cells from TCL1 Tg mice were positive for CD11b, a marker for monocytes and macrophages (Figure 5c ). Similarly staining for T-cells with CD4 and CD8 showed larger population of CD8 cells in the TCL1 Tg mice compared with the double Tg mice (Figure 5d ). This expansion in the population of CD8 cells in TCL1 Tg mice increased the CD8:CD4 ratio to~2:1 from the normal 1:1 ratio observed in the PTPROt/TCL1 double Tg mice (Figure 5d ) as well as in the NTg and PTPROt Tg mice (Supplementary Figure S1 ). These observations demonstrate that expression of PTPROt prevents infiltration of inflammatory cells into the spleen.
Double Tg mice survive longer than the TCL1 Tg mice. To determine whether the expression of PTPROt confers a survival advantage to TCL1 Tg mice, a group of TCL1 Tg (n = 47) and double Tg mice (n = 44) was monitored for survival. The median survival for double Tg mice was 389 days (95% confidence interval (CI): 346, 421), whereas that for TCL1 Tg mice was 333 days (95% CI: 313, 373). The log-rank test revealed that the survival probabilities between the two groups were significantly different (P-value = 0.0114; Figure 6 ), with increased survival of the double Tg mice over that of TCL1 Tg mice. This observation reinforces the tumor-suppressor characteristic of PTPROt.
Foxm1 is regulated by p53 through the BCR signaling pathway. To determine the mechanism of Foxm1 upregulation in the TCL1 Tg mice and its suppression by PTPROt in the double Tg mice, we used IPA to determine the most significantly altered transcription factors in the TCL1 Tg mice relative to the NTg mice and the double Tg mice. TP53 was the top-ranked transcription factor that was predicted to be inhibited in the TCL1 Tg mice in both comparisons. Conversely, TP53 was predicted as activated in the double Tg mice relative to the TCL1 Tg mice (Figure 7a ). Interestingly, TP53 can negatively regulate FOXM1 through its inhibition of E2F1. 29, 30 Analysis of DNA binding activity of p53 by electrophoretic mobility shift assay indeed demonstrated that it was higher in the double Tg mice compared with the TCL1 Tg mice (Figure 7b ). As p53 itself is regulated by serine phosphorylation, 31 it is likely that altered activity of p53 in the Tg mice was a result of signaling molecules regulated by tyrosine phosphorylation. Because PTPROt inhibits the BCR pathway by targeting Lyn kinase 14 and SYK, 13 we used a clinically active inhibitor against SYK (R406) to determine whether Foxm1 expression is regulated by PTPROt through this pathway. We also tested a new inhibitor, PCI-32765/ibrutinib that targets BTK in the BCR signaling pathway and has been recently approved by Food and Drug Administration for use in the treatment of CLL, for its effect on Foxm1 expression. Real-time RT-PCR demonstrated that treatment of spleen B-cells isolated from TCL1 Tg mice with the inhibitors resulted in suppression of Foxm1 (Figure 7c ). As expected, the expression of Ccl3 was also suppressed following inhibition of BCR signaling (Figure 7c ). We also observed that expression of p53 was higher in the inhibitor-treated cells (Figure 7d ). These observations suggest that inhibition of BCR signaling by PTPROt induces p53 that in turn represses Foxm1.
DISCUSSION
In this study, we have investigated, for the first time, the in vivo function of PTPROt in CLL through the generation of a Tg mouse with B-cell specific expression of PTPROt. We have demonstrated that these mice develop normally and have a normal lifespan. Further, phosphorylation of previously identified substrates of PTPROt, Lyn and SYK kinase, was suppressed in the B-lymphocytes but not the T-lymphocytes isolated from the spleens of the Tg mice. Importantly, these mice did not exhibit any significant changes in lymphocyte development. This observation indicates that any phenotypic and pathological alterations observed in the double Tg mice obtained by crossing the PTPROt Tg mice with the TCL1 Tg mice, a mouse model of CLL, is not a result of altered lymphocyte development due to exogenous expression of PTPROt.
Assessment of the pathology of double Tg mice demonstrated a decrease in spleen weight and the total number of spleen cells compared with the TCL1 Tg mice, suggesting that expression of PTPROt has a growth inhibitory effect in the background of TCL1 expression. Microarray analysis performed to explore the mechanism of PTPROt function showed that the gene expression profile of the TCL1 Tg mice exhibited oncogenic properties when compared with the non-transgenic mice and the double Tg mice. This suggests that the phenotype of the double Tg mice is similar to the NTg mice. 
Suppression of leukemic phenotype in CLL mouse model by PTPROt
A striking observation is the significant upregulation of Ccl3 (macrophage inflammatory protein 1a), a marker of CLL disease progression, 28 in the TCL1 Tg mice and its suppression in the double Tg mice. Consistent with its chemo-attractant function, 28, 32 the population of CD11b+ and CD8+ cells was higher in the TCL1 Tg mice but lower in the double Tg mice. As a consequence, the percentage of CD19+ B-cells was reduced in the TCL1 Tg mice compared with the double Tg mice. These results demonstrate that PTPROt can inhibit the infiltration of monocytes and T-lymphocytes that support the growth of CLL cells. 33 Another novel observation is the suppression of the oncogenic transcription factor Foxm1 and its targets in the double Tg mice. Foxm1, a proliferation-associated transcription factor belonging to the FOX family of transcription factor, is involved in the regulation of cell cycle genes and is an important target for cancer diagnosis and therapy. Although CLL has been traditionally known as a disease of decreased apoptosis rather than of increased proliferation, it is now recognized that CLL cells proliferate and that such proliferation has also been observed in the TCL1 Tg mice. 26 Upregulation of FOXM1 has not been previously reported in primary human CLL probably owing to the use of peripheral blood lymphocytes instead of spleen cells. It is conceivable that lymphocytes are proliferating in the spleen and become dormant once in circulation. It thus becomes important to target the expression of FOXM1 in the spleen lymphocytes to inhibit their proliferation and the increase in peripheral white blood cell counts.
Finally, the mechanism of Foxm1 regulation deserves comment. Previous studies have shown that BCR pathway regulates the expression of Ccl3. 27 As PTPROt is a negative regulator of kinases in this pathway, it is conceivable that suppression of Ccl3 in the double Tg mice is caused by inhibition of BCR signaling. However, no such regulation of Foxm1 has been studied. Interestingly, IPA of microarray data showed that TP53, a negative regulator of FOXM1, 29, 30 is inhibited in the TCL1 Tg mice compared with both NTg mice and the double Tg mice. To determine whether TP53, and consequently FOXM1, are also regulated by the BCR signaling pathway, we used inhibitors against specific kinases in the pathway. This study indeed showed that Foxm1 expression is also under the control of BCR signaling in B-lymphocytes. Importantly, this study has delineated a relationship between important tumor-suppressors PTPROt and p53 and their role in the regulation of the oncogene Foxm1. In this context, it is noteworthy that loss of p53 associated with deletion of chromosome 17p in CLL patients is considered to cause aggressive phenotype. 34, 35 
